Aethlon Medical stock analysis
Aethlon Medical (EJU) Stock Price & Analysis
EJU Stock Chart & Stats
- Day’s Range
- EUR 1.89 - EUR 1.89
- 52-Week Range
- EUR 1.89 - EUR 1.89
- Previous Close
- EUR 1.89
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 8.02M
- Enterprise Value
- -EUR 2.98M
- Total Cash (Recent Filing)
- EUR 4.93M
- Total Debt (Recent Filing)
- EUR 367.61K
- Price to Earnings (P/E)
- ―
- Beta
- -0.09
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- -2.43
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development Progress
Reaching the final cohort is a meaningful development milestone for the Hemopurifier program and moves the company closer to a complete clinical data package. The reported absence of device-related serious adverse events or dose-limiting toxicity supports continued evaluation, although efficacy remains unproven.
Platform Expansion
Evaluation across several disease areas increases the potential application set for the Hemopurifier beyond its current oncology focus. Continued evidence that the device can bind or remove disease-implicated extracellular vesicles may support broader partnerships and future clinical development if human findings are validated.
Cost Control And Runway
Lower operating spending and newly raised capital improve near-term execution capacity by slowing cash consumption while clinical work advances. A stated runway of at least 12 months gives management time to complete the current study, analyze results and pursue regulatory or funding discussions.
Bears Say
Persistent Operating Losses
The absence of meaningful revenue leaves Aethlon without demonstrated commercial operating leverage and makes progress dependent on future commercialization or external funding. Continued losses and deeply negative cash flow reduce financial resilience and constrain the company’s ability to fund development internally.
Early-Stage Clinical Uncertainty
Small, preliminary cohorts cannot establish whether observed biomarker changes are reproducible, clinically meaningful or generalizable to broader patient populations. Until statistical analysis and larger studies are completed, regulatory progress and the commercial value of the Hemopurifier remain materially uncertain.
Ownership Dilution And Strategic Change
The proposed transaction materially changes the ownership and strategic profile of Aethlon, leaving current shareholders with a small minority position and contingent value rights. Although the PIPE is expected to fund operations, the structure reduces existing holders’ participation in future upside from the combined company.
Aethlon Medical News
M&A News: Aethlon Medical Stock (AEMD) Rockets 400% After North Immunology Deal to Fight Eczema
Aethlon Medical ($AEMD) shares were nearly 400% higher in pre-market trading today after it announced it was merging with North Immunology to drive forward its innovative eczema treatment. Aethlon said
EJU FAQ
What was Aethlon Medical’s price range in the past 12 months?
What is Aethlon Medical’s market cap?
When is Aethlon Medical’s upcoming earnings report date?
How were Aethlon Medical’s earnings last quarter?
Is Aethlon Medical overvalued?
Does Aethlon Medical pay dividends?
What is Aethlon Medical’s EPS estimate?
How many shares outstanding does Aethlon Medical have?
What happened to Aethlon Medical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Aethlon Medical?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Aethlon Medical
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- James Frakes
- Employees
- 9
- Website
- www.aethlonmedical.com
- Address
- 11555 Sorrento Valley Road, San Diego, CA, 92121, US
Aethlon Medical (EJU) Earnings & Revenues
EJU Earnings Call
Earnings Call SentimentNeutral
The call balanced tangible near-term progress with clear caveats. Positives include advancement into the final clinical cohort, encouraging Cohort 2 biomarker signals, a peer-reviewed Long COVID preclinical publication, ongoing R&D expansion, an improved post-quarter cash position following a ~$4.0M financing, and an 11.9% reduction in operating expenses. Key negatives are that clinical observations are preliminary and based on very small sample sizes, statistical analyses are pending, dosing is logistically constrained, and larger trials will require additional capital or partnerships. Overall, the company shows disciplined resource management and meaningful early scientific signals but faces validation, scale and funding headwinds before efficacy or regulatory clarity can be established.
View all DE:EJU earnings summariesEJU Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 3 | 4 |
| Technical Analysis | 1 | 1 | 0 |
| Moving Averages | 6 | 2 | 4 |
